Pharmacokinetics of Bolus 5-Fluorouracil: Relationship Between Dose, Plasma Concentrations, Area-Under-the-Curve and Toxicity

References

• Pinedo HM, Peters GJ. Fluorouracil: biochemistry and pharmacology. J Clin Oncol 1988; 6: 1653–1664.
   PubMed Web of Science ®Google Scholar
• Grem JL. 5-Fluorouracil: forty-plus and still ticking. A review of its preclinical and clinical development. Invest New Drugs 2000; 18: 299–313.
   PubMed Web of Science ®Google Scholar
• Cano JP, Rigault JP, Aubert C, Carcassonne Y, Seitz JF. Determination of 5-fluorouracil in plasma by GC/MS using an internal standard: application to pharmacokinetics. Bull Cancer 1979; 66: 67–74.
   PubMed Web of Science ®Google Scholar
• Erlichman C, Fine S, Elhakim T. Plasma pharmacokinet-ics of 5FU given by continuous infusion with allopurinol. Cancer Treat Rep 1986; 70: 903–904.
   PubMedGoogle Scholar
• Fleming RA, Milano GA, Etienne MC, et al. No effect of dose, hepatic function, or nutritional status on 5-FU clearance following continuous (5-day), 5-FU infusion. Br J Cancer 1992; 66: 668–672.
   PubMed Web of Science ®Google Scholar
• Heggie GD, Sommadossi JP, Cross DS, Huster WJ, Diasio RB. Clinical pharmacokinetics of 5-fluorouracil and its metabolites in plasma, urine and bile. Cancer Res 1987; 47: 2203-2206.
   Google Scholar
• MacMillan WE, Wolberg WH, Welling PG. Pharma-cokinetics of fluorouracil in humans. Cancer Res 1978; 38: 3479–3482.
   PubMed Web of Science ®Google Scholar
• Milano G, Etienne MC, Renee N et al. Relationship between fluorouracil systemic exposure and tumor response and patient survival. J Clin Oncol 1994; 12: 1291–1295.
   Google Scholar
• Schneider M, Etienne MC, Milano G et al. Phase II trial of cisplatin, fluorouracil, and pure folinic acid for locally advanced head and neck cancer: a pharmacokinetic and clini-cal survey. J Clin Oncol 1995; 13: 1656–1662.
   Google Scholar
• Thyss A, Milano G, Renee N, Vallicioni J, Schneider M, Demard F. Clinical pharmacokinetic study of 5-FU in continu-ous infusion for head and neck cancer. Cancer Chemother Pharmacol 1986; 16: 64–66.
   PubMed Web of Science ®Google Scholar
• Vokes EE, Mick R, Kies MS et al. Pharmacodynamics of fluorouracil-based induction chemotherapy in advanced head and neck cancer. J Clin Oncol 1996; 14: 1663–1671.
   PubMed Web of Science ®Google Scholar
• Gamelin EC, Danquechin-Dorval EM, Dumesnil YF et al. Relationship between 5-fluorouracil (5-FU) dose intensity and therapeutic response in patients with advanced colorectal cancer receiving infusional therapy containing 5-FU. Cancer 1996; 77: 441–451.
   PubMed Web of Science ®Google Scholar
• Gamelin E, Boisdron-Celle M, Delva R et al. Long-term weekly treatment of colorectal metastatic cancer with fluo-rouracil and leucovorin: results of a multicentric prospective trial of fluorouracil dosage optimization by pharmacokinetic monitoring in 152 patients. J Clin Oncol 1998; 16: 1470–1478.
   Google Scholar
• Hillcoat BL, McCulloch PB, Figueredo AT, Ehsan MH, Rosenfeld JM. Clinical response and plasma levels of 5-fluo-rouracil in patients with colonic cancer treated by drug infu-sion. Br J Cancer 1978; 38: 719–724.
   PubMed Web of Science ®Google Scholar
• Van Groeningen CJ, Peters GJ, Schornagel JH et al. Phase I clinical and pharmacokinetic study of oral 5-1 in patients with advanced solid tumors. J Clin Oncol 2000; 18: 2772-2779.
   Google Scholar
• Larsson PA, Carlsson G, Gustavsson B, Graf W, Glimelius B. Different intravenous administration techniques for 5-fluorouracil - pharmacokinetics and pharmacodynamic effects. Acta Oncol 1996; 35: 207–212.
   PubMed Web of Science ®Google Scholar
• Van Groeningen CJ, Pinedo HM, Heddes J et al. Pharmacokinetics of 5-fluorouracil assessed with a sensitive mass spectrometric method in patients on a dose escalation schedule. Cancer Res 1988; 48: 6956–6961.
   Google Scholar
• Van Kuilenburg AB. Dihydropyrimidine dehydrogenase and the efficacy and toxicity of 5-fluorouracil. Eur J Cancer 2004; 40: 939–950.
   PubMed Web of Science ®Google Scholar
• Maring JG, van Kuilenburg AB, Haasjes J, et al. Reduced 5-FU clearance in a patient with low DPD activity due to heterozygosity for a mutant allele of the DPYD gene. Br J Cancer 2002; 86: 1028-1033.
   Google Scholar
• Kobayashi K, Jodrell DI, Ratain MJ. Pharmacodynamic-pharmacokinetic relationships and therapeutic drug monitor-ing. Cancer Surv 1993; 17: 51–78.
   PubMedGoogle Scholar
• Diasio RB, Lu ZH. Dihydropyrimidine dehydrogenase activity and fluorouracil chemotherapy. J Clin Oncol 1994; 12: 2239–2242.
   PubMed Web of Science ®Google Scholar
• Yoshida T, Araki E, Iigo M et al. Clinical significance of monitoring serum levels of 5-fluorouracil by continuous infu-sion in patients with advanced colonic cancer. Cancer Chemother Pharmacol 1990; 26: 352–354.
   Google Scholar
• Beal SL, Sheiner LB. Estimating population kinetics. Crit Rev Biomed Eng 1982; 8: 195–222.
   PubMed Web of Science ®Google Scholar
• Sheiner LB, Beal SL. Evaluation of methods for esti-mating population pharmacokinetic parameters. III. Monoexponential model: routine clinical pharmacokinetic data. J Pharmacokinet Biopharm 1983; 11: 303–319.
   PubMedGoogle Scholar
• Di Paolo A, Danesi R, Vannozzi F, et al. Limited sam-pling model for the analysis of 5-fluorouracil pharmacokinetics in adjuvant chemotherapy for colorectal cancer. Clin Pharmacol Ther 2002; 72: 627–637.
   PubMed Web of Science ®Google Scholar
• Van Kuilenburg AB, Van Lenthe H, Van Gennip AH. Radiochemical assay for determination of dihydropyrimidinase activity using reversed-phase high-performance liquid chro-matography. J Chromatogr B Biomed Sci Appl 1999; 729: 307–314.
   PubMed Web of Science ®Google Scholar
• Van Kuilenburg AB, Van Lenthe H, Tromp A, Veltman PC, Van Gennip AH. Pitfalls in the diagnosis of patients with a partial dihydropyrimidine dehydrogenase deficiency. Clin Chem 2000; 46: 9–17.
   PubMed Web of Science ®Google Scholar
• Moore MJ, Kaizer L, Erlichman C et al. Clinical and pharmacological study of 5-fluorouracil, leucovorin and inter-feron alpha in advanced colorectal cancer. Cancer Chemother Pharmacol 1995; 37: 86–90.
   Google Scholar
• Peters GJ, Schornagel JH, Milano GA. Clinical phar-macokinetics of antimetabolites. Cancer Surv 1993; 17: 123–156.
   PubMedGoogle Scholar
• Codacci-Pisanelli G, Van der Wilt CL, Smid K, Noordhuis P, Voorn D, Pinedo HM, Peters GJ. High-dose 5-fluorouracil with uridine-diphosphoglucose rescue increases thymidylate synthase inhibition but not 5-fluorouracil incorpo-ration into RNA in murine tumors. Oncology 2002; 62: 363–370.
   PubMed Web of Science ®Google Scholar
• Glimelius B, Jakobsen A, Graf W et al. Bolus injection (2-4 min) versus short-term (10-20 min) infusion of 5-fluo-rouracil in patients with advanced colorectal cancer: a prospective randomised trial. Eur J Cancer 1998; 34: 674–678.
   Google Scholar
• Hidalgo M, Villalona-Calero MA, Eckhardt SG et al. Phase I and pharmacologic study of PN401 and fluorouracil in patients with advanced solid malignancies. J Clin Oncol 2000; 18: 167–177.
   PubMed Web of Science ®Google Scholar
• Tognella S. Uridine rescue of the FUra toxicity. The possible role of Uridine diphosphoglucose (UDPG). Anticancer Res 1992; 12: 1923–1924.
   Google Scholar
• Van Groeningen CJ, Peters GJ, Pinedo HM. Reversal of 5-fluorouracil-induced toxicity by oral administration of uri-dine. Ann Oncol 1993; 4: 317–320.
   PubMed Web of Science ®Google Scholar